Wednesday, November 07, 2007 9:30:46 AM
You are right that there are cost savings to insurance companies if more accurate collection allows less follow-up or prevents false negatives, where the woman will need expensive surgery down the road. I don't know how CYCR would go about showing that there are fewer false negatives using their collection since any study would take a long time, years not months, to show that women whose sample is collected with the e2 have fewer cancers a year or two later.
I am just a small investor trying to get a handle on the company's plan to be profitable in the near term. I know that people within the company are surely asking and answering these same questions. I am only questioning because I don't know, and a good deal of what I see here is more hopeful speculation than real calculation based upon information. But then again maybe the company doesn't want to share that information at this time.
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM